Winfast Holding
VC Fund
Shanghai, China
Winfast Holding is a fund-management & investment group.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Winfast Holding invests in
Health CareMedicalBiotechnologyMedical DeviceBiopharma
Stages Winfast Holding invests in
Series ASeries BSeries DSeedAngel
Countries Winfast Holding invests in
China
Investment Focus
Industry
- Health Care 7 (50%)
- Medical 5 (36%)
- Biotechnology 5 (36%)
- Medical Device 4 (29%)
- Biopharma 3 (21%)
Stage
- Series A 4 (29%)
- Series B 4 (29%)
- Series D 2 (14%)
- Seed 1 (7%)
- Angel 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Huanxin Medical
|
Huanxin Medical is an innovative medical device company that specializes in the research and development of interventional medical devices. | Series B / Aug 14, 2025 | |
Zhiren Jingxing
|
Zhiren Jingxing is a new material research and development platform focused on the study, development, and manufacture of alloy materials. | $14.1M / Series A / Jan 26, 2024 | |
|
UniXell
|
UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders. | $31.4M / Seed / Mar 14, 2022 | |
TOPI Imaging Technology
|
TOPI Imaging Technology is a medical device firm providing OCT retinal diagnostic system and sweep optical biometer. | $31.4M / Series B / Dec 14, 2021 | |
Huasun Energy
|
Huasheng New Energy specializes in the R&D, production and sales of high-efficiency silicon heterojunction cells and components. | Series A / Nov 01, 2021 | |
TransThera Biosciences
|
TransThera Biosciences is a biotech company that focuses on the discovery and development of small-molecule new drugs. Its research and business strategies zero in clear unmet medical needs in oncology and inflammatory diseases through internal research and open innovation. The company was founded in 2016 and is headquartered in Nanjing, Jiangsu. | $100M / Series D / Jul 25, 2021 | |
Meiwei Dental Group
|
Meiwei Dental Medical Group is affiliated to Tianyi Group and is committed to opening up the overall health management of the whole people from the prevention, opening up to create the “China's first platform for oral medicine”, and through strategic investment, standard output, medical technology improvement and brand management as excellentin China. Oral medical brands and experts empower and achieve personalized development, and jointly promote the rapid development of the private dental health industry. Meiwei Dental cooperates with DNV GL, an internationally recognized certification body, to establish the first internationally-advanced dental clinic management system and medical standard “M+” management certification, and empowers partners through the construction of “five-one-one license”. Achieve scientific research and innovation and talent cultivation academicization, based on SaaS cloud platform informationization, medical and therapeutic environment comfort, medical service specialization, consumables and equipment refinement. Through the introduction of the "business partner" mechanism, the company has created a "stable and win-win" community of destiny, with the principle of complementarity and mutual integration, and the cooperation of partners in the medical capital, talent, technology, market, management and other dimensions. Carry out all-round empowerment. At present, Meiwei has invested in the acquisition of Weile Dental, Xinqiao Oral, Zhongshan Oral, DUANG DUANG Children's Oral, Meier Oral, Love Tooth, Hanmei Oral, Zhimei Dental, Tsinghua Sunshine Oral, Houcheng Oral, Hengmei Oral, Small The White Rabbit has a total of 12 dental chain brands covering 35 cities and 130 dental hospitals and clinics. | $154.3M / Series B / Jul 16, 2021 | |
Hanyu Medical
|
Hanyu Medical is one of the first domestic companies to develop, produce, and sell transcatheter mitral valve repair devices. At present, the company’s core product is Valve Clamp, a mitral valve interventional device, which is used for minimally invasive interventional treatment of mitral valve regurgitation diseases. | $76.9M / Series D / Mar 15, 2021 | |
Ark Biosciences
|
Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development of innovative therapeutics to address unmet medical need, especially in the area of respiratory viral infection and viral hepatitis, for global and China market. We strive to build a science-driven biopharmaceutical company that aims to be a leader inantiviral drug discovery and development. To achieve so, we aspire for the excellence of science and be innovative. We operate with a razor-sharp focus and aggressiveness with a timely and cost efficient manner. We create a healthy and rewarding work environment for employees, and seek a superior rate of return for investors and partners. | $86K / Series C / Jan 22, 2021 | |
Haihe Biopharma
|
HaiHe Biopharma is a developer of innovative anti tumor drugs designed to overcome complex diseases and improve pharmacological evaluation. The company focuses on discovery, development and commercialization of innovative anti-tumor drugs, pharmacological efficacy evaluation and provide products including novel topoisomerase I inhibitors and oralc-Met highly selective inhibitors, enabling customers to improve their health conditions and research quality in an efficient manner. | $171M / Series B / Jul 24, 2020 | |
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does Winfast Holding invest in?
Winfast Holding invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Winfast Holding last invest?
The most recent investment recorded for Winfast Holding closed in Aug 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
